What should I know about Chugai Pharmaceutical?
Chugai Pharmaceutical is a Japanese drugmaker, founded in 1925 and based in Tokyo, that discovers, develops and sells prescription medicines, mainly in oncology, immunology and neuroscience. It is part of the Roche Group: Roche controls 61.12% of Chugai's voting rights, but Chugai operates as a separate listed company. It also earns royalties and milestone payments from medicines it discovered and licensed to others. Chugai trades on the Tokyo Stock Exchange.
What are Chugai Pharmaceutical's main drugs?
Chugai's sales in Japan are driven by Vabysmo, Polivy, Enspryng, Phesgo, Elevidys and Lunsumio, according to a report on its first-half 2026 results. Its overseas business, which is mostly supply to Roche, is led by Hemlibra and Nemluvio. Chugai also earns royalties from Foundayo (orforglipron), an oral GLP-1 drug it licensed to Eli Lilly, which started contributing in the second quarter of 2026, per its H1 results.
What is Chugai Pharmaceutical currently developing?
According to its first-half 2026 results, Chugai's pipeline includes NXT007, described as a next-generation growth driver, for which two Phase 3 studies have begun. A third macrocyclic peptide project, AQUA07, has entered the clinic, with a Phase 1 study in ALK-positive non-small cell lung cancer about to start dosing. Enspryng's US application for thyroid eye disease has received FDA priority review. The company made eight regulatory filings in Japan in the first half of the year.
Is Chugai Pharmaceutical publicly traded, and how big is it?
Yes. Chugai is listed on the Tokyo Stock Exchange. On 24 July 2026 its shares closed at ¥7,416, giving a market capitalisation of about ¥12.45 trillion, according to a market report. Revenue for the first half of 2026 was ¥663.3 billion, up 14.7%, and the company forecasts full-year 2026 revenue of about ¥1.345 trillion.